Literature DB >> 17967742

Interactions of HIV and methamphetamine: cellular and molecular mechanisms of toxicity potentiation.

J L Cadet1, I N Krasnova.   

Abstract

Methamphetamine (METH) is a highly addictive psychostimulant drug, whose abuse has reached epidemic proportions worldwide. METH use is disproportionally represented among populations at high risks for developing HIV infection or who are already infected with the virus. Psychostimulant abuse has been reported to exacerbate the cognitive deficits and neurodegenerative abnormalities observed in HIV-positive patients. Thus, the purpose of the present paper is to review the clinical and basic observations that METH potentiates the adverse effects of HIV infection. An additional purpose is to provide a synthesis of the cellular and molecular mechanisms that might be responsible for the increased toxicity observed in co-morbid patients. The reviewed data indicate that METH and HIV proteins, including gp120, gp41, Tat, Vpr and Nef, converge on various caspase-dependent death pathways to cause neuronal apoptosis. The role of reactive microgliosis in METH- and in HIV-induced toxicity is also discussed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17967742     DOI: 10.1007/bf03033915

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  303 in total

1.  Neuroprotective role of melatonin in methamphetamine- and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced dopaminergic neurotoxicity.

Authors:  S F Ali; J L Martin; M D Black; Y Itzhak
Journal:  Ann N Y Acad Sci       Date:  1999       Impact factor: 5.691

2.  Central nervous system pathology in pediatric AIDS: an autopsy study.

Authors:  D W Dickson; A L Belman; Y D Park; C Wiley; D S Horoupian; J Llena; K Kure; W D Lyman; R Morecki; S Mitsudo
Journal:  APMIS Suppl       Date:  1989

3.  Critical implication of the (70-96) domain of human immunodeficiency virus type 1 Vpr protein in apoptosis of primary rat cortical and striatal neurons.

Authors:  Emmanuelle N Sabbah; Bernard P Roques
Journal:  J Neurovirol       Date:  2005-12       Impact factor: 2.643

4.  Methamphetamine-related stroke: four cases.

Authors:  J A Perez; E L Arsura; S Strategos
Journal:  J Emerg Med       Date:  1999 May-Jun       Impact factor: 1.484

5.  Higher cortical and lower subcortical metabolism in detoxified methamphetamine abusers.

Authors:  N D Volkow; L Chang; G J Wang; J S Fowler; D Franceschi; M J Sedler; S J Gatley; R Hitzemann; Y S Ding; C Wong; J Logan
Journal:  Am J Psychiatry       Date:  2001-03       Impact factor: 18.112

6.  Biosynthesis, cleavage, and degradation of the human immunodeficiency virus 1 envelope glycoprotein gp160.

Authors:  R L Willey; J S Bonifacino; B J Potts; M A Martin; R D Klausner
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

Review 7.  Clinical effects and management of methamphetamine abuse.

Authors:  Frank Romanelli; Kelly M Smith
Journal:  Pharmacotherapy       Date:  2006-08       Impact factor: 4.705

8.  Dopamine quinone formation and protein modification associated with the striatal neurotoxicity of methamphetamine: evidence against a role for extracellular dopamine.

Authors:  M J LaVoie; T G Hastings
Journal:  J Neurosci       Date:  1999-02-15       Impact factor: 6.167

9.  Methamphetamine potentiates HIV-1 Tat protein-mediated activation of redox-sensitive pathways in discrete regions of the brain.

Authors:  Govinder Flora; Yong Woo Lee; Avindra Nath; Bernhard Hennig; William Maragos; Michal Toborek
Journal:  Exp Neurol       Date:  2003-01       Impact factor: 5.330

10.  Cross-talk between two cysteine protease families. Activation of caspase-12 by calpain in apoptosis.

Authors:  T Nakagawa; J Yuan
Journal:  J Cell Biol       Date:  2000-08-21       Impact factor: 10.539

View more
  36 in total

1.  Short communication: quantitative proteomic plasma profiling reveals activation of host defense to oxidative stress in chronic SIV and methamphetamine comorbidity.

Authors:  Gurudutt Pendyala; Sunia A Trauger; Gary Siuzdak; Howard S Fox
Journal:  AIDS Res Hum Retroviruses       Date:  2010-10-07       Impact factor: 2.205

2.  Do psychoactive drugs have a therapeutic role in compulsivity? Studies on schedule-induced polydipsia.

Authors:  Elena Martín-González; Ángeles Prados-Pardo; Santiago Mora; Pilar Flores; Margarita Moreno
Journal:  Psychopharmacology (Berl)       Date:  2018-01-08       Impact factor: 4.530

Review 3.  HIV-1 gp120 and drugs of abuse: interactions in the central nervous system.

Authors:  Peter S Silverstein; Ankit Shah; James Weemhoff; Santosh Kumar; D P Singh; Anil Kumar
Journal:  Curr HIV Res       Date:  2012-07       Impact factor: 1.581

4.  Methamphetamine activates nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and induces human immunodeficiency virus (HIV) transcription in human microglial cells.

Authors:  Emily S Wires; David Alvarez; Curtis Dobrowolski; Yun Wang; Marisela Morales; Jonathan Karn; Brandon K Harvey
Journal:  J Neurovirol       Date:  2012-05-22       Impact factor: 2.643

Review 5.  Amphetamine toxicities: classical and emerging mechanisms.

Authors:  Bryan K Yamamoto; Anna Moszczynska; Gary A Gudelsky
Journal:  Ann N Y Acad Sci       Date:  2010-02       Impact factor: 5.691

6.  Antiretrovirals, Methamphetamine, and HIV-1 Envelope Protein gp120 Compromise Neuronal Energy Homeostasis in Association with Various Degrees of Synaptic and Neuritic Damage.

Authors:  Ana B Sanchez; Giuseppe P Varano; Cyrus M de Rozieres; Ricky Maung; Irene C Catalan; Cari C Dowling; Natalia E Sejbuk; Melanie M Hoefer; Marcus Kaul
Journal:  Antimicrob Agents Chemother       Date:  2015-10-19       Impact factor: 5.191

Review 7.  Effects of HIV and Methamphetamine on Brain and Behavior: Evidence from Human Studies and Animal Models.

Authors:  Virawudh Soontornniyomkij; James P Kesby; Erin E Morgan; Amanda Bischoff-Grethe; Arpi Minassian; Gregory G Brown; Igor Grant
Journal:  J Neuroimmune Pharmacol       Date:  2016-08-02       Impact factor: 4.147

8.  Prepulse inhibition in HIV-1 gp120 transgenic mice after withdrawal from chronic methamphetamine.

Authors:  Brook L Henry; Mark A Geyer; Mahalah R Buell; William Perry; Jared W Young; Arpi Minassian
Journal:  Behav Pharmacol       Date:  2014-02       Impact factor: 2.293

9.  "Frontal systems" behaviors in comorbid human immunodeficiency virus infection and methamphetamine dependency.

Authors:  María J Marquine; Jennifer E Iudicello; Erin E Morgan; Gregory G Brown; Scott L Letendre; Ronald J Ellis; Reena Deutsch; Steven Paul Woods; Igor Grant; Robert K Heaton
Journal:  Psychiatry Res       Date:  2013-11-13       Impact factor: 3.222

10.  Behavioral effects of chronic methamphetamine treatment in HIV-1 gp120 transgenic mice.

Authors:  Brook L Henry; Mark A Geyer; Mahalah Buell; William Perry; Jared W Young; Arpi Minassian
Journal:  Behav Brain Res       Date:  2012-08-31       Impact factor: 3.332

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.